The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

In the rapidly evolving field of drug discovery, single-cell analysis has become an invaluable tool for understanding cellular heterogeneity and molecular | Drug Discovery And Development ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

This article introduces a multi-step preparative purification workflow for synthetic peptides using liquid ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

LUND, SWEDEN / ACCESS Newswire / March 21, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end o ...